Journal
GENETIC TESTING AND MOLECULAR BIOMARKERS
Volume 17, Issue 3, Pages 188-194Publisher
MARY ANN LIEBERT INC
DOI: 10.1089/gtmb.2012.0258
Keywords
-
Funding
- Baun Foundation Trust at the Cumballa Hill Hospital and Heart Institute, Mumbai
- Department of Biotechnology (DBT), Government of India
- DBT
Ask authors/readers for more resources
Aims: Drug-metabolizing enzymes play a major role in determining the outcome of drug therapy. N-acetyltransferase-2 (NAT2) is one of the main enzymes involved in metabolism of isoniazid used in treatment of tuberculosis (TB). Several variations in the NAT2 gene give rise to multiple haplotypes that phenotypically code for different acetylator status. The objective was to generate a more unambiguous picture of the NAT2 scenario in India as compared to that obtained from polymerase chain reaction-restriction fragment length polymorphism methods. Methods: Full-gene-sequencing analysis of NAT2 was carried out in 181 healthy Indian subjects from different regional groups. Results: A total of 33 diplotypes were recorded from six known single-nucleotide polymorphisms. The overall frequency of the slow acetylator haplotypes detected in this study was 65%, followed by 26% and 9% intermediate and rapid acetylators, respectively. Of the slow acetylator alleles, the NAT2*5B/*6A occurred in 25% of the study subjects. Conclusions: The study indicates that the frequency of slow acetylator alleles is high in the adult Indian population. Since the prevalence of TB is high in this population, pharmacogenetic testing for NAT2 alleles may be advisable before start of therapy with isoniazid to prevent drug toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available